Last Price$394.92.3%
Market Cap$150.5B
LTM Research & Development Expenses (R&D)
$1,455.0M
YoY Growth
+4.8%
3Y CAGR
+5.6%
5Y CAGR
+8.4%
Stock quality & Intrinsic value
7/10
22.7% overvalued
Stryker Corporation Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $279.8M | $324.6M | $375.3M | $367.8M | $336.2M | $393.9M | $462.0M | $471.0M | $536.0M | $614.0M | $625.0M | $715.0M | $787.0M | $862.0M | $971.0M | $984.0M | $1,235.0M | $1,454.0M | $1,388.0M | $1,466.0M |
Overvalued or undervalued?
Check the intrinsic value for SYK
and see if it's the right time to invest.
Stryker Corporation (SYK) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Stryker CorporationSYK
$1,455.0M
4.8%
5.6%
8.4%
Median Peer Set
$816.8M
4.3%
4.4%
7.5%
Abbott LaboratoriesABT
$2,839.0M
4.0%
1.2%
3.1%
Medtronic plcMDT
$2,723.0M
0.8%
(0.0%)
2.9%
Koninklijke Philips N.V.PHG
$1,891.0M
(7.5%)
(1.1%)
(1.5%)
Boston Scientific CorporationBSX
$1,615.0M
14.1%
10.3%
6.6%
Edwards Lifesciences CorporationEW
$1,081.2M
4.6%
7.7%
8.4%
DexCom, Inc.DXCM
$552.4M
9.2%
(2.9%)
15.1%
Align Technology, Inc.ALGN
$364.2M
5.0%
13.3%
18.3%
Zimmer Biomet Holdings, Inc.ZBH
$328.9M
(28.3%)
(11.8%)
(6.0%)
Insulet CorporationPODD
$219.6M
7.1%
11.1%
11.1%
STERIS plcSTE
$107.4M
2.5%
10.6%
10.8%
SYK key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 4,871.5 14.3% | 5,405.6 11.0% | 6,000.5 11.0% | 6,718.2 12.0% | 6,723.1 0.1% | 7,320.0 8.9% | 8,307.0 13.5% | 8,657.0 4.2% | 9,021.0 4.2% | 9,675.0 7.2% | 9,946.0 2.8% | 11,325.0 13.9% | 12,444.0 9.9% | 13,601.0 9.3% | 14,884.0 9.4% | 14,351.0 (3.6%) | 17,108.0 19.2% | 18,449.0 7.8% | 20,498.0 11.1% | 22,595.0 10.2% |
| Cost of Goods Sold (COGS) | 1,713.9 | 1,848.7 | 1,865.2 | 2,131.4 | 2,183.7 | 2,285.7 | 2,811.0 | 2,781.0 | 2,977.0 | 3,291.0 | 3,344.0 | 3,830.0 | 4,271.0 | 4,663.0 | 5,188.0 | 5,294.0 | 6,140.0 | 6,871.0 | 7,401.0 | 8,155.0 |
% margin | 3,157.6 64.8% | 3,556.9 65.8% | 4,135.3 68.9% | 4,586.8 68.3% | 4,539.4 67.5% | 5,034.3 68.8% | 5,496.0 66.2% | 5,876.0 67.9% | 6,044.0 67.0% | 6,384.0 66.0% | 6,602.0 66.4% | 7,495.0 66.2% | 8,173.0 65.7% | 8,938.0 65.7% | 9,696.0 65.1% | 9,057.0 63.1% | 10,968.0 64.1% | 11,578.0 62.8% | 13,097.0 63.9% | 14,440.0 63.9% |
| Operating Expenses | 2,142.9 | 2,429.9 | 2,828.0 | 3,032.9 | 2,878.0 | 3,159.4 | 3,734.0 | 4,060.0 | 4,740.0 | 5,138.0 | 4,445.0 | 5,171.0 | 5,710.0 | 6,378.0 | 6,791.0 | 6,817.0 | 8,281.0 | 8,536.0 | 9,209.0 | 10,751.0 |
| Research & Development Expenses (R&D) | 279.8 | 324.6 | 375.3 | 367.8 | 336.2 | 393.9 | 462.0 | 471.0 | 536.0 | 614.0 | 625.0 | 715.0 | 787.0 | 862.0 | 971.0 | 984.0 | 1,235.0 | 1,454.0 | 1,388.0 | 1,466.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,814.3 | 2,061.7 | 2,391.5 | 2,625.1 | 2,506.3 | 2,707.3 | 3,150.0 | 3,466.0 | 4,066.0 | 4,336.0 | 3,610.0 | 4,137.0 | 4,552.0 | 5,099.0 | 5,356.0 | 5,361.0 | 6,427.0 | 6,455.0 | 6,920.0 | 7,685.0 |
% margin | 998.8 20.5% | 1,074.3 19.9% | 1,307.3 21.8% | 1,519.0 22.6% | 1,594.4 23.7% | 1,751.4 23.9% | 1,686.0 20.3% | 1,741.0 20.1% | 1,256.0 13.9% | 1,246.0 12.9% | 1,861.0 18.7% | 2,166.0 19.1% | 2,290.0 18.4% | 2,537.0 18.7% | 2,713.0 18.2% | 2,223.0 15.5% | 2,584.0 15.1% | 2,841.0 15.4% | 3,888.0 19.0% | 3,689.0 16.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 34.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 155.0 | 102.0 | 68.0 | 94.0 | 75.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 34.8 | 52.6 | 0.0 | 0.0 | 34.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 287.0 | 315.0 | 337.0 | 158.0 | 356.0 | 0.0 |
| Pre-tax Income | 1,003.3 | 1,103.8 | 1,370.1 | 1,580.2 | 1,623.9 | 1,729.6 | 1,686.0 | 1,705.0 | 1,212.0 | 1,160.0 | 1,735.0 | 1,921.0 | 2,063.0 | 2,356.0 | 2,562.0 | 1,954.0 | 2,281.0 | 2,683.0 | 3,673.0 | 3,492.0 |
% effective tax rate | 328.1 32.7% | 326.1 29.5% | 383.4 28.0% | 432.4 27.4% | 516.5 31.8% | 456.2 26.4% | 341.0 20.2% | 407.0 23.9% | 206.0 17.0% | 645.0 55.6% | 296.0 17.1% | 274.0 14.3% | 1,043.0 50.6% | (1,197.0) (50.8%) | 479.0 18.7% | 355.0 18.2% | 287.0 12.6% | 325.0 12.1% | 508.0 13.8% | 499.0 14.3% |
% margin | 675.2 13.9% | 777.7 14.4% | 1,017.4 17.0% | 1,147.8 17.1% | 1,107.4 16.5% | 1,273.4 17.4% | 1,345.0 16.2% | 1,298.0 15.0% | 1,006.0 11.2% | 515.0 5.3% | 1,439.0 14.5% | 1,647.0 14.5% | 1,020.0 8.2% | 3,553.0 26.1% | 2,083.0 14.0% | 1,599.0 11.1% | 1,994.0 11.7% | 2,358.0 12.8% | 3,165.0 15.4% | 2,993.0 13.2% |
| EPS | 1.60 | 1.91 | 2.48 | 2.81 | 2.79 | 3.21 | 3.48 | 3.41 | 2.66 | 1.36 | 3.82 | 4.40 | 2.73 | 9.50 | 5.57 | 4.26 | 5.29 | 6.23 | 8.34 | 7.86 |
| Diluted EPS | 1.57 | 1.89 | 2.44 | 2.78 | 2.77 | 3.19 | 3.45 | 3.39 | 2.63 | 1.34 | 3.78 | 4.35 | 2.68 | 9.34 | 5.48 | 4.20 | 5.22 | 6.17 | 8.25 | 7.76 |
% margin | 1,252.2 25.7% | 1,445.1 26.7% | 1,758.9 29.3% | 1,998.3 29.7% | 2,023.7 30.1% | 2,217.3 30.3% | 2,261.0 27.2% | 2,049.0 23.7% | 2,353.0 26.1% | 2,604.0 26.9% | 2,667.0 26.8% | 3,126.0 27.6% | 3,363.0 27.0% | 3,617.0 26.6% | 4,176.0 28.1% | 3,755.0 26.2% | 4,646.0 27.2% | 4,536.0 24.6% | 4,934.0 24.1% | 5,716.0 25.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Stryker Corporation's Research & Development Expenses (R&D)?
As of today, Stryker Corporation's last 12-month Research & Development Expenses (R&D) is $1,455.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Stryker Corporation's Research & Development Expenses (R&D) growth rate?
Over the last year, Stryker Corporation's Research & Development Expenses (R&D) growth was 4.8%. The average annual Research & Development Expenses (R&D) growth rates for Stryker Corporation have been 9.9% over the past three years, 8.4% over the past five years.
3) Is Stryker Corporation's Research & Development Expenses (R&D) growth rate Good?
Over the last year, Stryker Corporation's Research & Development Expenses (R&D) growth was 4.8%, which is higher than industry growth of (0.0%). It indicates that Stryker Corporation's Research & Development Expenses (R&D) growth is Bad.